Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroidectomy | 4 | 2025 | 35 | 2.890 |
Why?
|
| Thyroid Neoplasms | 8 | 2025 | 87 | 2.590 |
Why?
|
| Adrenal Gland Neoplasms | 4 | 2026 | 52 | 1.810 |
Why?
|
| Hypoparathyroidism | 2 | 2025 | 8 | 1.810 |
Why?
|
| Tumor Microenvironment | 3 | 2026 | 182 | 1.610 |
Why?
|
| Postoperative Complications | 4 | 2025 | 1320 | 1.420 |
Why?
|
| Checklist | 2 | 2021 | 72 | 1.270 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 524 | 1.180 |
Why?
|
| Research Design | 3 | 2021 | 588 | 1.070 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 102 | 1.070 |
Why?
|
| Breast Neoplasms | 4 | 2025 | 1222 | 1.040 |
Why?
|
| Graves Disease | 2 | 2022 | 18 | 0.830 |
Why?
|
| Adrenocortical Adenoma | 1 | 2022 | 3 | 0.770 |
Why?
|
| Adenoma | 1 | 2022 | 70 | 0.740 |
Why?
|
| Surgeons | 2 | 2023 | 191 | 0.720 |
Why?
|
| Fluoroimmunoassay | 1 | 2021 | 4 | 0.680 |
Why?
|
| Patient Readmission | 1 | 2025 | 448 | 0.670 |
Why?
|
| Statistics as Topic | 1 | 2021 | 147 | 0.640 |
Why?
|
| Biomedical Research | 1 | 2021 | 261 | 0.540 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 699 | 0.500 |
Why?
|
| Emergency Service, Hospital | 1 | 2025 | 1149 | 0.490 |
Why?
|
| California | 2 | 2025 | 177 | 0.440 |
Why?
|
| Hematoma | 2 | 2023 | 84 | 0.440 |
Why?
|
| Humans | 30 | 2026 | 65100 | 0.410 |
Why?
|
| Incidence | 3 | 2025 | 1418 | 0.380 |
Why?
|
| Neoplasm Staging | 4 | 2025 | 544 | 0.370 |
Why?
|
| Retrospective Studies | 7 | 2025 | 6860 | 0.370 |
Why?
|
| Hemorrhage | 2 | 2023 | 285 | 0.340 |
Why?
|
| Registries | 2 | 2025 | 913 | 0.340 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2026 | 2244 | 0.320 |
Why?
|
| Middle Aged | 11 | 2025 | 18254 | 0.310 |
Why?
|
| Female | 15 | 2025 | 34000 | 0.290 |
Why?
|
| Risk Factors | 4 | 2025 | 5423 | 0.280 |
Why?
|
| Predictive Value of Tests | 4 | 2026 | 1113 | 0.280 |
Why?
|
| Adult | 7 | 2025 | 17351 | 0.260 |
Why?
|
| Young Adult | 4 | 2025 | 4810 | 0.260 |
Why?
|
| Immunotherapy | 2 | 2026 | 274 | 0.240 |
Why?
|
| Adenocarcinoma | 2 | 2022 | 366 | 0.240 |
Why?
|
| Adrenal Glands | 1 | 2026 | 35 | 0.230 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 863 | 0.230 |
Why?
|
| Adolescent | 3 | 2025 | 6305 | 0.220 |
Why?
|
| Aged | 6 | 2025 | 14946 | 0.220 |
Why?
|
| Medical Oncology | 1 | 2025 | 69 | 0.220 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 60 | 0.210 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 64 | 0.210 |
Why?
|
| Heart Diseases | 1 | 2026 | 223 | 0.200 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2023 | 71 | 0.190 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2022 | 2 | 0.190 |
Why?
|
| Endocrine System Diseases | 1 | 2022 | 11 | 0.190 |
Why?
|
| G-Quadruplexes | 1 | 2022 | 7 | 0.190 |
Why?
|
| Air Pollution | 1 | 2023 | 41 | 0.190 |
Why?
|
| Iodine | 1 | 2022 | 21 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 218 | 0.180 |
Why?
|
| Air Pollutants | 1 | 2023 | 99 | 0.180 |
Why?
|
| Male | 9 | 2025 | 31017 | 0.180 |
Why?
|
| Databases, Factual | 1 | 2025 | 882 | 0.170 |
Why?
|
| Incidental Findings | 1 | 2021 | 51 | 0.170 |
Why?
|
| Tissue Array Analysis | 1 | 2021 | 39 | 0.170 |
Why?
|
| Sports Medicine | 1 | 2021 | 28 | 0.170 |
Why?
|
| Patient Care | 1 | 2021 | 79 | 0.170 |
Why?
|
| Glioblastoma | 1 | 2022 | 161 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 1698 | 0.160 |
Why?
|
| Peer Review, Research | 1 | 2021 | 47 | 0.160 |
Why?
|
| Lipids | 1 | 2022 | 328 | 0.160 |
Why?
|
| Diagnosis, Differential | 1 | 2022 | 991 | 0.150 |
Why?
|
| Sensitivity and Specificity | 1 | 2022 | 1163 | 0.150 |
Why?
|
| Cancer Survivors | 1 | 2022 | 129 | 0.150 |
Why?
|
| Fluorescent Dyes | 1 | 2021 | 202 | 0.150 |
Why?
|
| Breast | 1 | 2021 | 191 | 0.150 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2018 | 7 | 0.140 |
Why?
|
| Knowledge Bases | 1 | 2018 | 6 | 0.140 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2018 | 37 | 0.130 |
Why?
|
| Eosinophilia | 1 | 2018 | 37 | 0.130 |
Why?
|
| Plants | 1 | 2018 | 50 | 0.130 |
Why?
|
| Databases, Genetic | 1 | 2018 | 90 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 433 | 0.120 |
Why?
|
| Treatment Outcome | 2 | 2024 | 5784 | 0.110 |
Why?
|
| Quinolines | 1 | 2015 | 47 | 0.110 |
Why?
|
| Plasmodium | 1 | 2015 | 34 | 0.110 |
Why?
|
| Sample Size | 1 | 2015 | 67 | 0.110 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2015 | 40 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 1656 | 0.110 |
Why?
|
| Genomics | 1 | 2018 | 384 | 0.110 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2015 | 45 | 0.110 |
Why?
|
| Antimalarials | 1 | 2015 | 126 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 194 | 0.100 |
Why?
|
| Netherlands | 1 | 2013 | 26 | 0.100 |
Why?
|
| Prognosis | 3 | 2026 | 1779 | 0.100 |
Why?
|
| Neck | 1 | 2013 | 46 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 169 | 0.100 |
Why?
|
| Malaria | 1 | 2015 | 158 | 0.100 |
Why?
|
| Canada | 1 | 2013 | 154 | 0.100 |
Why?
|
| Heart Ventricles | 1 | 2015 | 267 | 0.100 |
Why?
|
| Stroke Volume | 1 | 2015 | 342 | 0.100 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 279 | 0.100 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 332 | 0.090 |
Why?
|
| Reoperation | 1 | 2013 | 301 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 930 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 804 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1141 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1386 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 244 | 0.080 |
Why?
|
| United States | 3 | 2023 | 8093 | 0.080 |
Why?
|
| Disease Progression | 2 | 2026 | 1219 | 0.080 |
Why?
|
| Algorithms | 1 | 2015 | 1048 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1630 | 0.070 |
Why?
|
| Pandemics | 2 | 2022 | 675 | 0.060 |
Why?
|
| Time Factors | 1 | 2013 | 3762 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2026 | 222 | 0.060 |
Why?
|
| Receptors, Progesterone | 1 | 2025 | 110 | 0.060 |
Why?
|
| Receptors, Estrogen | 1 | 2025 | 130 | 0.050 |
Why?
|
| Adrenalectomy | 1 | 2023 | 25 | 0.050 |
Why?
|
| Puerto Rico | 1 | 2023 | 138 | 0.050 |
Why?
|
| Alcohols | 1 | 2022 | 13 | 0.050 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 12 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2022 | 60 | 0.050 |
Why?
|
| Isoxazoles | 1 | 2022 | 15 | 0.050 |
Why?
|
| Seasons | 1 | 2023 | 139 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2023 | 145 | 0.050 |
Why?
|
| Mortality | 1 | 2023 | 161 | 0.040 |
Why?
|
| Temperature | 1 | 2023 | 316 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 1585 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 134 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2021 | 278 | 0.040 |
Why?
|
| Transcriptome | 1 | 2023 | 399 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2023 | 794 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2023 | 528 | 0.040 |
Why?
|
| Anxiety | 1 | 2022 | 426 | 0.040 |
Why?
|
| Internet | 1 | 2022 | 468 | 0.030 |
Why?
|
| Genetic Research | 1 | 2018 | 9 | 0.030 |
Why?
|
| Genome, Plant | 1 | 2018 | 6 | 0.030 |
Why?
|
| Cell Line | 1 | 2022 | 2023 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 1477 | 0.030 |
Why?
|
| Gene Ontology | 1 | 2018 | 38 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 1566 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2018 | 45 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2018 | 67 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2018 | 126 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 89 | 0.030 |
Why?
|
| New South Wales | 1 | 2016 | 4 | 0.030 |
Why?
|
| North America | 1 | 2016 | 114 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 103 | 0.030 |
Why?
|
| Peptide Elongation Factor 2 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Nomograms | 1 | 2015 | 20 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2018 | 394 | 0.030 |
Why?
|
| Life Cycle Stages | 1 | 2015 | 20 | 0.030 |
Why?
|
| Plasmodium berghei | 1 | 2015 | 21 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 174 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 415 | 0.030 |
Why?
|
| Plasmodium vivax | 1 | 2015 | 52 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 96 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1259 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 407 | 0.030 |
Why?
|
| Software | 1 | 2018 | 400 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2763 | 0.030 |
Why?
|
| Community Health Services | 1 | 2015 | 127 | 0.030 |
Why?
|
| Animals | 2 | 2026 | 21308 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 844 | 0.020 |
Why?
|
| Plasmodium falciparum | 1 | 2015 | 257 | 0.020 |
Why?
|
| Health Behavior | 1 | 2015 | 484 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1162 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 869 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 1693 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 2061 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 2096 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 5607 | 0.010 |
Why?
|
| Child | 1 | 2015 | 4612 | 0.010 |
Why?
|